Heart Failure in East Asia

Yutao Guo¹,², Gregory YH Lip² and Amitava Banerjee*¹

¹University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom; ²Department of Geriatric Cardiology, Chinese PLA General Hospital, Beijing, China;

Abstract: Heart failure (HF) carries a major burden of disease in East Asia, with high associated risk of mortality and morbidity. In recent decades, the epidemiology of HF has changed with social and economical development in East Asia. The burden of HF is still severe in East Asia. The prevalence of HF ranges from 1.3% to 6.7% throughout the region. As aetiological factors, ischaemic heart disease has increased and valvular disease reduced in most East Asian countries. Diuretics are the most commonly used drugs (51.0%-97%), followed by renin-angiotensin system (RAS) inhibitors (59%-77%), with angiotensin-converting enzyme inhibitors, ACEI, (32%-52%) and has angiotensin-2 receptor blockers, ARBs (31%-44%) in similar proportions. Beta-blocker use has also increased in recent years. Total mortality from HF ranges from 2% to 9% in China, Taiwan, Singapore, Thailand, and Japan. Age>65 years, diabetes mellitus, anaemia, renal dysfunction and atrial fibrillation (AF) are associated with adverse outcome. More prospective, region-specific data are still required, particularly regarding new drug therapies such as eplerenone and ivabradine.

Keywords: Heart failure, epidemiology, management, East Asia.

INTRODUCTION

Heart failure (HF) is increasingly prevalent worldwide and is associated with significant morbidity and mortality. The lifetime risk of developing HF is one in five at the age of 40 years [1]. Over 5 million individuals in the United States have HF, and more than 550,000 are diagnosed annually [2]. It is becoming a burden in health care, which results in greater $39 billion annual cost in North American and £716 million (1.8% of the total NHS budget) in the United Kingdom [3]. HF is a global epidemic, but clinical characteristics and treatment may vary for patients with HF across geographic regions [4].

In China, 4.2 million individuals have HF, and cardiovascular disease is the leading cause of death [5-6]. In Japan, 1.0 million individuals were estimated to have HF in 2005, and this figure is expected to rise to 1.3 million by 2035 [7].

During the last 20 years, changes in society and economy in East Asia countries, such as the aging of the population and medical progress, have led to changes in the epidemiology of HF [8]. Some region-specific, epidemiological studies have been conducted in East Asia, especially in China and Japan [9-26]. These research studies included the populations in both urban and rural areas, and investigated the epidemiology of different age-groups of patients.

The present review based on recent evidence, aims to update the epidemiology and management of HF in East Asian countries, including the prevalence/incidence, aetiology/comorbidities, treatment, prognosis, HF with preserved ejection fraction (HFPEF), and HF in older patients in East Asia.

SEARCH STRATEGY

We searched PUBMED between 1 January 1990 and 30 June 2012 for articles concerned with the epidemiology of HF, risk factors for HF, drug treatment and prognosis of HF in populations in East Asia. The search terms were: HF, PEF, prevalence, incidence, aetiology, risk factor, drug management, prognosis, outcome, mortality, rehospitalization, China, Chinese, Japan, Japanese, Taiwan, Hong Kong, Korea, Mongolia, Malaysia, Singapore, Thailand, East Asia or the combination of these key words. We included epidemiological studies and clinical trials. Study populations of fewer than 720 people and duplicates were excluded. The articles meeting the eligibility criteria with full text were retrieved by literature searches for reports on the epidemiology and treatment of HF in East Asia. Of these, 42 articles qualified for inclusion.

PREVALENCE AND INCIDENCE OF HF

The prevalence of HF was 6.7% in Malaysia, 4.5% in Singapore, and 1.3% in China respectively [16, 19, 20]. The reported incidence of HF in the Chinese population is 0.7 to 0.9 per 1000 [13, 15]. There are 1.8 million individuals with congenital cardiac abnormalities in China and 500,000 new cases of HF every year [27]. A hospital-based study showed that the prevalence of Chinese patients with HF by age < 40, 40 - 49, 50 - 59, 60 - 69, and 70 - 79 years was 6.7%, 10.7%, 18.8%, 23.5%, and 30.8% respectively (p<0.01),
while community-based studies demonstrated approximately doubling prevalence with each decade of age with 0.3% at age 35-44 years, 0.6% at age 45-54 years, 1.3% at age 55-64 years, 2.6% at age 65-74 years, and 4.1% at age ≥75 years [11, 13]. On the other hand, the age of Chinese patients admitted for HF has significantly reduced in recent years: 66.4 ± 14.1 years between 2000 and 2003, 64.9 ± 14.4 years between 2004 and 2006, and 64.2 ± 14.8 years between 2007 and 2010 (P < 0.01) [11]. Age-adjusted hospital admission rates for HF increased by 38% in 1990s in Singapore [19], and hospital admissions for HF were about 35% higher in Malaysians than in Chinese in this study [19].

AETIOLOGY AND COMORBITIES OF HF

In recent decades, the ischemic aetiology for HF has increased in East Asia populations but not as greatly as in Western populations. In a USA national registry, out-patients with HF had a relatively higher proportion of ischaemic aetiology (52.6%, 71.1% and 72.9% for those aged <65, 65-76 and >76 years, respectively) and prior myocardial infarction (MI) (34.3%, 42.8% and 41.5% for the respective ages) [28]. Asian Americans were reported to have higher prevalence of HF after acute MI [29].

Aetiology and comorbidities of HF in East Asia are given in Figure 1. The proportion of coronary artery disease (CAD) ranged from 25% to 47% in HF populations in mainland China, Taiwan, Hong Kong, Malaysia, and Japan [9-26]. Hypertension was the most likely comorbidity in Japanese patients with HF, with the highest rate of 74% [25], however, the lowest rate of hypertension (19%) was in Malaysia [15]. The prevalence of hypertension in HF was 23%-47% in mainland China [9-11, 14], 38.3%-41.3% in Taiwan [15], and 37% in Hong Kong [10]. Moreover, valvular disease appears to be a less common aetiology of HF in East Asia, reported in 15%-35% of patients with HF in most of countries, but only 4% in Malaysia [18]. Diabetes and atrial fibrillation (AF) are also common comorbidities, with 12%-36% and 21%-42% prevalence respectively among HF patients [9-26]. Furthermore, renal dysfunction and anaemia are risk factors of HF. A hospital-based study of patients with HF in Canada indicated that Chinese patients had the highest rates of renal disease compared to white populations [30].

Data about comorbidities of HF were consistent in one community-based study and three hospital-based studies in China [9-11, 14]. The most common comorbidities were CAD, hypertension, and diabetes mellitus. Dilated cardiomyopathy, valvular heart disease, and AF were common comorbidities in these Chinese populations with HF. A 10-year survey of hospital in-patients with HF showed rheumatic valvular heart disease was the most frequent cause in patients aged less than 40 years old and dilated cardiomyopathy was most likely in patients aged 40-59 years [11]. Renal dysfunction was also common in Chinese patients with CHF, and the China Heart Survey showed that 34.3% patients with CHF had chronic kidney disease [12]. AF was another main cause of Chinese HF patients in 1990s and early 2000s, with the rate of 20.6%-23.2%.

Two Japanese studies (CHART-1, CHART-2) showed that an increasing trend towards ischemic aetiology (26.4%-47.1%) and comorbidities with diabetes (19.5-23.3%) and hypertension (47.4%-74.3%) in Japanese HF patients [20, 24, 25, 31], confirmed by the JCARE-CARD which revealed a prevalence of CAD in 32% of patients [22]. In the CHART-1 study between 2000 and 2005, CAD accounted for only 26.4% and the proportion of patients older than 65 years was 66% [20], but in the CHART-2 study between 2006 and 2010, CAD as a comorbidity increased to 47.1%, hypertension was 74.3%, and diabetes was 23.3% [22]. Additionally, JCARE-CARD showed that 57% patients with HF had anaemia [23], and the prevalence of AF was common (40%) in hospital-HF patients [21].

DRUG TREATMENT FOR HF IN EAST ASIA

In East Asian countries, diuretics were the most common treatment, used in between 50.9% and 96.9% of patients, followed by renin-angiotensin system (RAS) inhibitors (59.2-76.5%). Prevalence of angiotensin-converting enzyme inhibitor (ACEI) and angiotensin-2 receptor blocker (ARB) use was 31.5-52.2% and 30.9-44.4% respectively. Nitrates were used in 23.3-80.0%, and betablocker use varied from 19.5-49.0% in China, Taiwan, and Japan, to only 9.3% in Malaysia. Aspirin was used in 41.2% of HF patients in Taiwan, 47.2% in Japan, and 55.7% in Malaysia. Warfarin was reported to be used in 40.8% Japanese patients with HF [9-26] (Fig. 2). The relatively high rates of aspirin and warfarin usage may reflect the underlying high prevalence of CAD and AF in these populations, but population-based data are lacking.

---

**Fig. (1).** Aetiology and comorbidities in studies of HF in East Asia. CAD: coronary artery disease. AF: atrial fibrillation.
Nitrates, diuretics, digitalis, ACEI, and beta-blocker were the most commonly used agents in Chinese patients with chronic HF. Nearly half of patients with NYHA (New York Heart Association) Class III-IV were treated with the combination of ACEI and beta-blocker, or diuretic, digitalis, ACEI and beta-blocker. Beta-blocker therapy was most likely used in patients with NYHA Class II-III [14]. Although the administration of ACEI and beta-blockers increased in recent years, their application in clinical practice did not achieve the level proposed by recent guidelines for HF management [32, 33]. Diuretics were the most commonly used drugs, in both younger (74.4%) and older (76.9%) patients in Taiwan, followed by ACEI and/or ARB and aspirin15.

Beta-blocker use increased in the last decade, whilst diuretics and digitalis decreased in Japanese cohorts with HF. The usage of RAS inhibitors and beta-blockers for overt HF patients in the CHART-1 and CHART-2 studies increased from 69.1% to 72.3% and from 27.9% to 49.0%, respectively. In contrast, the usage rate of loop diuretics and digitalis decreased from 76.3% to 50.9% and from 48.1% to 23.5%, respectively.

New pharmacological therapies proposed by recent consensus guidelines for the management of HF [33], such as eplerenone and ivabradine, are less likely to be used in clinical practice in East Asia. There is very limited research data on these drugs in East Asian patients, who are under-represented in recent clinical trials in HF, e.g. only 8% of Asian patients in the SHIFT trial [34-35].

**ANTITHROMBOTIC TREATMENT IN HF IN EAST ASIA**

The comorbidities related to HF (such as CAD, AF) lead to a high risk of thromboembolic events, including stroke, pulmonary embolism and peripheral arterial embolism, whilst coronary ischaemic events also contribute to the progression of heart failure. CAD as a major aetiology of HF has increased with the societal and epidemiologic transition in East Asian countries and the prevalence of AF among patients with HF was 21-42% in those countries [9-26]. In a Japanese cohort study, 15% of HF patients were reported to suffer stroke [23]. The rate of aspirin use was consistent across Japan, Malaysia, and Taiwan (41.2-55.7%) [15, 18, 23].

Warfarin was used in 40.8% patients with HF in Japan, while 35% patients had AF and 15% patients suffered the stroke in this cohort [23]. However, only 5.1-5.2% patients with HF used warfarin in Malaysia and Taiwan [15, 18]. There were limited epidemiologic data from East Asia to evaluate the prevalence of comorbidities related to HF which may increase risk of thrombosis. Further research is required to provide such data in order to inform use of antithrombotic treatment for stroke prevention in HF patients.
To date, four major randomized controlled trials of antithrombotic therapy in HF have been performed [36-39]. There was no significant overall difference in the composite end point of ischemic stroke, intracerebral hemorrhage, or death between warfarin and aspirin in WARCEF and there is no evidence to support routine anticoagulant therapy in HF patients without AF. As in other clinical trials, Asian patients are greatly under-represented.

**DEVICE THERAPY**

Cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) therapies have not been widely used in treatment of HF in East Asia. CRT with defibrillator (CRT-D) became available in Japan in 2006 [40]. Large-scale epidemiological data regarding CRT-D, CRT-P and ICD are lacking in East Asian countries, and prospective data are required.

**CARDIAC REHABILITATION AND TELEMONITORING IN HF**

There are scarce data on cardiac rehabilitation and telemonitoring or telemedicine in the management of HF in East Asia. A nationwide survey on the implementation of cardiac rehabilitation following acute myocardial infarction (AMI) showed that 0-9% of Japanese hospitals provided outpatient cardiac rehabilitation programs [41]. A Japanese study including 442 patients with AMI or coronary artery bypass graft surgery (CABG) suggested less favourable physiological and psychosocial outcomes in women than men [42]. Small studies suggest that short educational programmes in the outpatient setting can improve long-term outcomes in HF [43-44], but other studies show mixed results, and that cardiac rehabilitation may increase patient anxiety [45-47]. There may be a role for Chinese qigong exercise in cardiac rehabilitation [48].

**PROGNOSIS AND OUTCOME OF HF**

Total mortality from HF was 2.2-8.8% in China, Taiwan, Singapore, Thailand, and Japan [19, 22, 23, 49]. 30-day mortality was similar in mainland China and Taiwan at 5.3% and 3.9% respectively [15]. In a 15-year trend analysis (from 1993 to 2007) in China, mortality of young patients with HF reduced [9], however, 30-day mortality in those individuals aged over 80 years increased from 9.8% to 20.0%. In this Chinese population, the 30-day hospital mortality showed a downward trend in HF patients with CAD, decreasing significantly from 9.3% in 1993-1997 to 3.8% in 2003-2007 (P<0.001) [50]. In another Chinese cohort with chronic HF, including 6453 patients with mean follow-up of 3 years, HF mortality was 30.1% in CAD, 44.9% in dilated cardiomyopathy (DCM), 36.2% in hypertensive heart disease (HHD), and 13.1% in rheumatic heart disease (RHD). Chronic systolic HF due to CAD, DCM and HHD carried a worse prognosis than that of RHD [51]. A higher hospital mortality rate was associated with an increased number of comorbidities [10]. Mortality from HF decreased from 7.3 per 10 000 in 1991 to 6.1 per 10 000 in 1998 in Singapore, and the decline was greater in women [19]. But, Indians and Malays had a worse outcome compared to the Chinese, probably due to higher mortality and HF readmission rates. A possible explanation for the worse outcomes in Indians could be due to the higher prevalence of diabetes mellitus and atherosclerotic vascular disease [52].

The rehospitalisation rate was 23.4% to 40% in three Japanese HF cohorts. In Thailand, the rehospitalisation rate within 30 days after discharge was 14.1% [50]. The length of hospital stay (LOS) > 5 days was the predictor of early readmission. Prognosis of HF in East Asia is shown in Table 1.

The prognosis and risk factors of HF in East Asia may be comparable with Western populations [53], although prospective data are lacking. Although survival after HF diagnosis has improved over time in North America, the death rate remains high, with nearly 50% of people diagnosed with HF dying within 5 years [1]. The reported 30-day in-hospital mortality of patients with HF ranged from 1.7-7.2% in North America [54]. The 30-day, 1-year, and 5-year case fatality rates after hospitalization for HF were 10.4%, 22%, and 42.3%, respectively [55]. Three-fourths of all HF hospitalizations are due to exacerbation of symptoms in patients with known HF. One-half of hospitalized HF patients experience readmission within 6 months [56, 57].

Consistent with the data from North America, diabetes was a significant prognostic risk factor in Japanese popula-

| Author          | Country | Patients (n) | Year       | 30-day Mortality | 1-year Mortality | Year | Mortality | Rehospitalization |
|----------------|---------|--------------|------------|-----------------|------------------|------|-----------|-------------------|
| Pei et al. [5] | China   | 7319         | 1993-2007  | 5.30%           | *                | 2007 | *         | *                 |
| Tseng et al. [11] | Taiwan | 2692         | 2005       | 3.90%           | *                | 2005 | *         | *                 |
| Ng et al. [15] | Singapore | 15774      | 1991-1998  | *               | *                | 1998 | 2.50%     | *                 |
| West et al. [39] | Singapore | 1029(HFPEF) | 2005-2009  | *               | *                | 2009 | 2.20%     | *                 |
| West et al. [39] | Thailand | 989(HFPEF)  | 2005-2009  | *               | *                | 2009 | 4.60%     | *                 |
| Koseki et al. [16] | Japan       | 721(HFPEF)  | 2003       | *               | *                | 2003 | 8%        | 23.4%             |
| Tsutsui et al. [17] | Japan       | 2685        | 2004-2005  | *               | *                | 2005 | 6.30%     | 40%               |
| Hamaguchi et al. [19] | Japan       | 2675        | 2004-2005  | *               | *                | 2005 | 8.8%      | 33.1%             |

HFPEF: Heart failure with preserved ejection fraction. *: Non-available data.
tion. Age was also associated with higher risks of adverse outcomes. In one study, 70% patients were over 65 years, and women were mostly over 70 years [21]. Anaemia and lower haemoglobin were independently associated with long-term adverse outcomes, including all-cause death, cardiac death, and rehospitalisation [22]. Japanese HF patients with reduced eGFR had a higher incidence of all-cause death and re-admission because of worsening CHF [24, 26], whilst renal dysfunction was independently associated with admission and re-admission because of worsening CHF [24, 26], whilst renal dysfunction was independently associated with advanced NYHA classes in a Chinese population [12]. Ventricular tachycardia or atrial fibrillation could impact the prognosis of patients with HF [58].

Advanced HF has an extremely high mortality and morbidity and is associated with poor quality of life. Future research is needed to identify high-risk individuals in order to improve patient outcomes.

HFPEF IN EAST ASIA

The majority of data from East Asia regarding HFPEF is from Japanese studies. Several multicentre-studies demonstrated the prevalence of HFPEF from 26% to 45% in Japan [24, 59]. Patients with PEF (EF ≥50%) were more likely to be older and female. Hypertension and hypertrophic cardiomyopathy were more common in HFPEF, whilst MI or CAD were less common (JCARE-CARD data) [20-22]. Patients with HFPEF had higher prevalence of AF, and anaemia was also common (20-30%) and associated with higher mortality in HF patients. Renal failure and diabetes mellitus were the common comorbidities in patients with HFPEF. Calcium channel blockers (CCB) were used commonly in patients with HFPEF, whilst ACEI and beta-blocker were less likely to be administered in those patients [60]. In-hospital mortality of HFPEF patients was 4.6% in Thailand and 2.2% in Singapore [50, 50]. CHART studies showed that all-cause mortality of Japanese patients with HFPEF at 1, 2, and 3 years was 7%, 16%, and 22%, respectively [24]. HFPEF patients had in-hospital mortality of 6.5%, which was not different from patients with reduced EF (<40%) after multivariable adjustment (JCARE-CARD data) [22]. There was no significant difference in survival analysis for all-cause mortality or cardiac mortality between patients with reduced and preserved EF. Rehospitalization rates were 23.7% and 25.7% in reduced and preserved EF patients respectively, with no difference between groups (p=0.47).

ELDERLY HF IN EAST ASIA

The prevalence of HF increased in proportion with aging. Hospital-based studies showed that the prevalence of HF in patients aged 60 years was 23.5-30.8% in China. The annual incidence of HF was 14 per 1000 in men and 20 per 1000 in women older than 85 years in Hong Kong [16], and 22 per 1000 population in elderly people in Taiwan [15]. Hypertension was the most common cause of patients aged 60 years in a Chinese HF cohort, and multiple comorbidities were predominant in the elderly compared to the younger patients [8]. Therapy with nitrates, ACEI and ARB was most common in patients aged over 60 years compared to the patients aged less than 60 years. Combination therapy with diuretic, digitalis, ACEI, and beta-blockers was common in the elderly with CHF. Beta-blocker use was used with equal frequency in elderly and young Chinese patients with HF. Patients greater than 85 years have a 25-fold higher risk of heart failure hospitalization, longer length of in-hospital stay, higher total medical expenditure and higher in-hospital mortality [15]. The 1-year mortality rate increased with age, reaching 40% for patients older than 85 years in Hong Kong [16]. The mortality of young patients with HF reduced during recent years in mainland China, but the mortality of very elderly patients (aged over 80 years) did not significantly decrease (Fig. 3).

The proportion of elderly population is high in Japan. The prevalence of HFPEF patients older than 65 years was 66% (CHART-1 study) [24]. 70% of patients with HF were over 65 years, and women with HF were mostly over 70 years in Japan [21]. Among patients aged over 70 years with HFPEF, valvular heart disease was the most frequent aetiology in CHART-1 study in the early 2000s. However, subsequent Japanese studies, including CHART-2, JCARE-GENERAL and JCARE-CARD, showed that hypertension in patients with HF increased in prevalence and became the

![Fig. (3). Prevalence and mortality of HF in Chinese population with age.](image-url)
most common comorbidity. Older age was also associated with the adverse outcome and 1-year mortality rate was 9.1% in HF patients with mean age of 74 years [21].

Further detailed data from individual studies regarding the epidemiology and management of HF in East Asia are shown in the Appendix.

CONCLUSION

The prevalence of HF ranged from 1.3 to 6.7% in East Asian countries, with increasing prevalence with age. In terms of aetiology of HF, ischemic heart disease has increased and valvular disease decreased in this region during the last 20 years. Patients with HF and preserved EF were more likely to be older, female, and to have hypertensive heart disease. The mortality of HF remains high, and increasing age, diabetes, anaemia, renal dysfunction, and AF are associated with adverse outcome. Although the usage of ACEI, ARB, and beta-blocker therapy has increased in recent years, diuretics, nitrates, and digitalis are the most commonly used drugs. The increased usage of ACEI, ARB, and beta-blocker may reflect the increasing role of coronary artery disease as the aetiology of HF and increasing adherence to international guidelines. However, more evidence is needed in East Asian settings for novel drugs such as eplerenone and ivabradine. Antithrombotic treatment for prevention of thromboembolism in patients with HF in East Asia requires further research.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

Declared none.

Appendix

Table 1. Epidemiology and management of HF in East Asia

| Study | Country and Setting | Population (n) | Study Design and Date | Prevalence/Incidence, % | Aetiology/comorbidities, % | Drug |
|-------|---------------------|----------------|-----------------------|--------------------------|---------------------------|------|
|       |                     |                |                       |                          |                           |      |
| Pei et al. 2011 [6] | China | 7,319 CHF patients | Retrospective 1993-2007 | 30-day mortality: 5.3%  | Coronary heart disease: 37.2%  | 1993-1998: Coronary heart disease: 37.2%  |
|       |                     | Age: 59.6(16.9) |                       | Male: 5.4% Female: 5.2%  | Hypertension: 23.3%  | Hypertension: 23.3%  |
|       |                     | Male: 62.1%    |                       |                          | Diabetes mellitus: 12.3% | Diabetes mellitus: 12.3%  |
|       |                     |                |                       |                          | Rheumatic valvar disease: 35.2% | Rheumatic valvar disease: 35.2%  |
|       |                     |                |                       |                          | 2003-2007: Coronary heart disease: 46.8% | 2003-2007: Coronary heart disease: 46.8%  |
|       |                     |                |                       |                          | Hypertension: 46.7%  | Hypertension: 46.7%  |
|       |                     |                |                       |                          | Diabetes mellitus: 21.1% | Diabetes mellitus: 21.1%  |
|       |                     |                |                       |                          | Rheumatic valvar disease: 16.6% | Rheumatic valvar disease: 16.6%  |
| Yin et al. 2011 [7] | China Beijing (Urban) | 6,949 patients with HF | Retrospective 1993-2007 | Coronary artery disease: 45.0% |  |  |
|       |                     | Male: 4344 Female: 2605 |                       | 45.0%  | Hypertension: 38.7%  | 1993-1998: Coronary heart disease: 37.2%  |
|       |                     |                |                       |                          | Valvular disease: 27.5% | Hypertension: 38.7%  |
|       |                     |                |                       |                          | Rheumatic valvar disease: 21.8% | Rheumatic valvar disease: 21.8%  |
|       |                     |                |                       |                          | Nonrheumatic valvar disease: 5.7% | Nonrheumatic valvar disease: 5.7%  |
|       |                     |                |                       |                          | Diabetes mellitus: 18.3% | Diabetes mellitus: 18.3%  |
| Yu et al. 2011 [8] | China Hubei (Urban, rural) | 12,450 patients | Retrospective 2000-2010 12 hospitals | <40 years: 6.67% (830/12 450) | Hypertension: 31.5% | Digitalis: 47.5%  |
|       |                     | Age: 62 (15) |                       | 40-49 years: 10.7% (1336/12 450) | Coronary heart disease: 28.2% | Diuretics: 68.8%  |
|       |                     | Male: 7166, 57.6% |                       | 50-59 years: 18.8% (2342/12 450) | Dilated cardiomyopathy: 26.6% | ACEI: 50.7%  |
|       |                     |                |                       | 60-69 years: 23.5% (2920/12 450) | Rheumatic valvar heart disease: 17.5% | β-blocker: 44.1% aldosterone antagonist : 53.1% |
|       |                     |                |                       | 70-79 years: 30.80% (3835/12 450) | Aetiology:  |  |
|       |                     |                |                       | ≥80 years: 9.53% (1187/12 450) | Age<40: rheumatic valvar heart disease |  |
|       |                     |                |                       | NYHA class I: 0.60%, II: 23.20%, III: 50.31%, IV: 26.50% | Age40-59: dilated cardiomyopathy |  |
|       |                     |                |                       |                          | Age≥60 years: hypertension |  |
| Study               | Country and Setting | Population (n) Age, Mean (SD) Male, % | Study Design and Date | Prevalence/Incidence, % Mortality, % Rehospitalization, % | Aetiology/comorbidities, % | Drug                      |
|---------------------|---------------------|--------------------------------------|-----------------------|----------------------------------------------------------|-----------------------------|---------------------------|
| Liu, et al. 2011 [9] | China               | 1006 patients with CHF Age: 71.3(9.9) Male: 63.7% | Retrospective 2005    |                                                          |                             | Chronic kidney disease: 34.3% |
| Yang, et al. 2010 [10] | China Xinjiang (6 localities, random sampling) | 8459 adults Age: 35 years over | Retrospective Communities-based | HF: 1.26% Male: 1.61%; Female: 0.93% (p<0.05) Age35-44:0.29% Age45-54:0.60% Age55-64:1.32% Age65-74:2.55% Age≥75 years:4.10% | Coronary heart disease:44.2% Rheumatic heart disease: 24.1% Pulmonary heart disease:19.0% Cardiomyopathy:4.8% | Nitrite:80.0% Diuretics:71.8% Digitalis:68.1% ACEI:52.2% Beta-blockers:19.5% |
| Ma, et al. 2007 [11] | China               | 5189 patients with CHF Age: 62.9(13.4) Male: 49.5% | Retrospective 1973-2002 |                                                          |                             | Coronary heart disease:44.2% Rheumatic heart disease: 24.1% Pulmonary heart disease:19.0% Cardiomyopathy:4.8% | Nitrite:80.0% Diuretics:71.8% Digitalis:68.1% ACEI:52.2% Beta-blockers:19.5% |
| Tseng, et al. 2011 [12] | Taiwan              | 2692 patients with HF Age: 73(13) Male: 55% | Retrospective Random sample of insurant 2005 | HF incidence: Age 20-60 years:88/100,000 Age≥65 years:21.8/100,000 In-hospital mortality: Total:3.9% Age 20-60 years: 2.7% Age≥65 years:4.2% | Coronary heart disease:44.2% Rheumatic heart disease: 24.1% Pulmonary heart disease:19.0% Cardiomyopathy:4.8% | Nitrite:80.0% Diuretics:71.8% Digitalis:68.1% ACEI:52.2% Beta-blockers:19.5% |
| Hung, et al. 2000 [13] | Hong Kong           | 6203 patients with HF Male age: 72.4 Female age: 77.5 Male: 44% | Retrospective 11 hospitals 1997 | Total incidence: 0.7 per 1000 Age> 85: 20 per 1000(women); 14 per 1000 (men) Mortality:32% | Coronary heart disease:44.2% Rheumatic heart disease: 24.1% Pulmonary heart disease:19.0% Cardiomyopathy:4.8% | Nitrite:80.0% Diuretics:71.8% Digitalis:68.1% ACEI:52.2% Beta-blockers:19.5% |
| Sanderson, et al.1995 [14] | Hong Kong           | 730 patients with HF Male: 44% | Prospective | Incidence Women: 3.8/1000 Men: 3.0/1000 | Coronary heart disease:44.2% Rheumatic heart disease: 24.1% Pulmonary heart disease:19.0% Cardiomyopathy:4.8% | Nitrite:80.0% Diuretics:71.8% Digitalis:68.1% ACEI:52.2% Beta-blockers:19.5% |
| Chong, et al. 2003 [15] | Malaysia            | 1435 acute medical admissions Male: 62.9% Mean age: 63.6 years | Retrospective Single-center | Ischaemic heart disease: 49.5%(48) Hypertension: 18.6%(18) Dilated cardiomyopathy: 4.1%(4) Valve disease: 4.1%(4) Anaemia:3.1%(3) | Coronary heart disease:44.2% Rheumatic heart disease: 24.1% Pulmonary heart disease:19.0% Cardiomyopathy:4.8% | Nitrite:80.0% Diuretics:71.8% Digitalis:68.1% ACEI:43.3%(42) Statin:2.2%(2) |
| Study                  | Country and Setting | Population (n) | Study Design and Date | Prevalence/Incidence, % | Aetiology/comorbidities, % | Drug               |
|-----------------------|---------------------|-----------------|-----------------------|--------------------------|---------------------------|--------------------|
| Ng, et al. 2003 [16]  | Singapore           | 15774 admissions | Retrospective 1991-1998 | HF: 4.5%                 |                           |                    |
|                       |                     | Age: 65 years   |                       |                          |                           |                    |
|                       |                     | Male: 46.6%     |                       |                          |                           |                    |
|                       |                     | Female: 53.4%   |                       |                          |                           |                    |
|                       |                     | Study Design    |                       | Prevalence/Incidence, %  | Aetiology/comorbidities, %| Drug               |
|                       |                     | and Date        |                       |                          |                           |                    |
|                       |                     | Population (n)  |                       |                          |                           |                    |
|                       |                     | Age, Mean (SD)  |                       |                          |                           |                    |
|                       |                     | Male, %         |                       |                          |                           |                    |
|                       |                     | Study Design    |                       | Prevalence/Incidence, %  | Aetiology/comorbidities, %| Drug               |
|                       |                     | and Date        |                       |                          |                           |                    |
|                       |                     | Population (n)  |                       |                          |                           |                    |
|                       |                     | Age, Mean (SD)  |                       |                          |                           |                    |
|                       |                     | Male, %         |                       |                          |                           |                    |
|                       |                     | Study Design    |                       | Prevalence/Incidence, %  | Aetiology/comorbidities, %| Drug               |
|                       |                     | and Date        |                       |                          |                           |                    |
|                       |                     | Population (n)  |                       |                          |                           |                    |
|                       |                     | Age, Mean (SD)  |                       |                          |                           |                    |
|                       |                     | Male, %         |                       |                          |                           |                    |
|                       |                     | Study Design    |                       | Prevalence/Incidence, %  | Aetiology/comorbidities, %| Drug               |
|                       |                     | and Date        |                       |                          |                           |                    |
|                       |                     | Population (n)  |                       |                          |                           |                    |
|                       |                     | Age, Mean (SD)  |                       |                          |                           |                    |
|                       |                     | Male, %         |                       |                          |                           |                    |

Note: The table continues with similar entries for each study, including other details such as age, gender distribution, prevalence/incidence, mortality, rehospitalization rates, and various medical conditions and treatments.
(Table 1) contd……

| Study            | Country and Setting | Population (n) | Study Design and Date | Prevalence/Incidence, % Mortality, % Rehospitalization, % | Aetiology/comorbidities, % | Drug     |
|------------------|---------------------|----------------|-----------------------|------------------------------------------------------------|-----------------------------|----------|
| Shiba, et al. 2008 [21] | Japan | 1,278 HF patients Age: 68.3(13.4) Male: 66% | Prospective 2000-2005 Mean follow-up:3.5 years | | Aetiology: Coronary artery disease: 25.4% Valvular heart disease: 26.4% Non-ischemic cardiomyopathy: 28.6% Comorbidities: Hypertension: 47.4% Diabetes: 18.9% Dyslipidemia: 16.7% AF: 41.8% |          |
| Shiba, et al. 2008 [21] | Japan | 1,278 HF patients Age: 68.3(13.4) Male: 66% | Prospective 2000-2005 Mean follow-up:3.5 years | | Aetiology: Coronary artery disease: 25.4% Valvular heart disease: 26.4% Non-ischemic cardiomyopathy: 28.6% Comorbidities: Hypertension: 47.4% Diabetes: 18.9% Dyslipidemia: 16.7% AF: 41.8% |          |
| Shiba, et al. 2011 [22] | Japan | 10,219 HF patients Age: 68.2(12.3) Male: 69.8% | Prospective Multicenter 2006-2010 | | Aetiology: Coronary artery disease: 47.1% Comorbidities: Hypertension: 74.3% diabetes: 23.3% | RAS inhibitors: 72.3% Diuretics : 50.9% Beta-blockers: 49.0% Digitalis 23.5% |
| Hamaguchi, et al. 2011 [23] | Japan | 2,675 patients with AF Age: 71(13) Male: 59.7% | Prospective 2004-2005 Average follow-up: 2.1 years | NYHA class I: 35.2%, II: 55.2%, III: 6.0%, IV: 3.6% All-cause death 14.7%(247) Cardiac death 8.8%(148) Rehospitalization 33.1%(557) | Aetiology: Ischemic: 32% Valvular: 27.7% Hypertensive: 24.6% Dilated cardiomyopathy: 18.2% Comorbidities: Hypertension: 52.9% Hyperuricemia: 46.8% Diabetes mellitus: 29.9% Dyslipidemia: 24.8% Prior stroke: 15.0% COPD: 6.7% Smoking: 37.7% Prior MI: 26.9% AF: 35.2% | Aspirin: 47.2% Warfarin: 40.8% Diuretics: 88.2% β-blocker: 48.6% Digitalis: 30.9% Nitrate: 23.3% ACEI: 37.4% ARB: 44.4% ACEI/ARB: 76.5% CCB: 25.2% Statin: 19.9% |

GP: general practice; COPD: chronic obstructive pulmonary disease; CHF: chronic heart failure; HFPEF: heart failure with preserved ejection fraction; CCB: calcium channel blocker; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin-converting enzyme receptor inhibitor; RAS: renin-angiotensin system

REFERENCES

[1] Roger VL, Go AS, Lloyd-Jones DM, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-e220.

[2] Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 557-73.

[3] National Clinical Guideline Centre (UK). Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update [Internet].London: Royal College of Physicians (UK); 2010 Aug. http://www.ncbi.nlm.nih.gov/books/NBK65340.

[4] Norton C, Georgiopoulou VV, Kalogeropoulos AP, et al. Epidemiology and cost of advanced heart failure. Prog Cardiovasc Dis 2011; 54: 78-85.
Heart Failure in East Asia

Current Cardiology Reviews, 2013, Vol. 9, No. 2

[5] Report on cardiovascular diseases in China. 2012. Hu Shengshou, Kong Lingzhi editors, National Center of Cardiovascular Diseases Encyclopedia of China Publishing House.

[6] He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med 2005; 353: 1124-34.

[7] Okura Y, Ramadan MM, Ohnme SO, et al. Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J. 2008; 72: 489-91.

[8] Djoussé L, Driver JA, Gaziano JM. Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA 2009; 302: 394-400.

[9] Pei ZY, Zhao YS, Li JY, et al. Fifteen-year evolving trends of etiology and prognosis in hospitalized patients with heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2011; 39: 434-9.

[10] Yin Q, Zhao Y, Li J, et al. The coexistence of multiple cardiovascular diseases is an independent predictor of the 30-day mortality of hospitalized patients with congestive heart failure: a study in Beijing. Clin Cardiol 2011; 34: 442-6.

[11] Yu SB, Cui HY, Qin M, et al. Characteristics of in-hospital patients with chronic heart failure in Hubei province from 2000 to 2010. Zhonghua Xin Xue Guan Bing Za Zhi 2011; 39: 549-52.

[12] Liu H, Shi H, Yu J, et al. Obesity and chronic kidney disease in patients with chronic heart failure: an insight from the China Heart Survey. Clin Exp Nephrol 2011; 15: 522-8.

[13] Yang YN, Ma YT, Liu F, et al. Incidence and distributing feature of chronic heart failure in adult population of Xinjiang. Zhonghua Xin Xue Guan Bing Za Zhi 2010; 38: 460-4.

[14] Ma JP, Wang L, Deng Q, et al. Retrospective analysis of drug treatment on inpatients with chronic heart failure. Zhonghua Liu Xin Xing Bing Xue Za Zhi 2007; 28: 78-82.

[15] Tseng CH. Clinical features of heart failure hospitalization in younger and elderly patients in Taiwan. Eur J Clin Invest 2011; 41: 597-604.

[16] Hung YT, Cheung NT, Ip S, et al. Epidemiology of heart failure in Hong Kong, 1997. Hong Kong Med J 2000; 6: 159-62.

[17] Sanderon JE, Chan SK, Chan WW, et al. The aetiology of heart failure in the Chinese population of Hong Kong—a prospective study of 730 consecutive patients. Int J Cardiol 1995; 51: 29-55.

[18] Chong AY, Rajaratnam R, Hussein NR, et al. Heart failure in a multiethnic population in Kuala Lumpur, Malaysia. Eur J Heart Fail 2003; 5: 569-74.

[19] Ng TP, Niti M. Trends and ethnic differences in hospital admissions and mortality for congestive heart failure in the elderly in Singapore, 1991 to 1998. Heart 2003; 89: 865-70.

[20] Koseki Y, Watanabe J, Shinozaki T, et al. CHART Investigators. Characteristics and 1-year prognosis of medically treated patients with chronic heart failure in Japan. Circ J 2003; 67: 431-6.

[21] Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, et al. Characteristics and outcomes of patients with heart failure in general practices and hospitals. Circ J 2007; 71: 403-5.

[22] Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. JCARE-CARD Investigators. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1893-900.

[23] Hamaguchi S, Tsuchihashi-Makaya M, Kinugawa S, et al. Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan. A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2009; 73: 1901-8.

[24] Shiba N, Shimokawa H. Chronic heart failure in Japan: implications of the CHART studies. Vasc Health Risk Manag 2008; 4: 103-13.

[25] Shiba N, Nochikas K, Miura M, et al. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan—first report from the CHART-2 study. Circ J 2011; 75: 823-33.

[26] Hamaguchi S, Kinugawa S, Goto D, et al. JCARE-CARD Investigators. Predictors of long-term adverse outcomes in elderly patients over 80 years hospitalized with heart failure. A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J 2011; 75: 2403-10.

[27] Report on cardiovascular diseases in China. 2009. Hu Shengshou, Kong Lingzhi editors, National Centre of Cardiovascular diseases Encyclopedia of China Publishing House.

[28] Yancy CW, Fonarow GC, Albert NM, et al. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am Heart J 2009; 157: 754-62.e2.

[29] Qian F, Ling FS, Deedwania P, et al. Get With The Guidelines Steering Committee and Investigators. Care and outcomes of Asian-American acute myocardial infarction patients: findings from the American Heart Association Get With The Guidelines—Coronary Artery Disease program. Circ Cardiovasc Qual Outcomes 2012; 5: 126-33.

[30] Kaul P, McAlister FA, Ezekowitz JA, et al. Ethnic differences in 1-year mortality among patients hospitalised with heart failure. Heart 2011; 97: 1048-53.

[31] Asanuma H, Kitakaze M. The largest cohort study opens a new era for the management of heart failure in Japan. Circ J 2011; 75: 775-6.

[32] Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-442.

[33] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-69.

[34] Swedberg K, Komajda M, Böhm M, et al. SHIFT Investigators. Ixabepilone and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.

[35] Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.

[36] Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004; 147: 1206-12.

[37] Massie BM, Collins JF, Ammon SE, et al. WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009; 119: 1616-24.

[38] Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK; HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006; 8: 428-32.

[39] Homma S, Thompson JL, Pullicino PM, et al. WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. JAMA 2007; 298: 1577-84.

[40] Momomura SI, Tsutsui H, Sugawara Y, et al. for the MOMUJ Study Investigators. Cyclic Efficacy of Cardiac Resynchronization Therapy With an Implantable Defibrillator in a Japanese Population. Circ J 2012; 76: 1911-9.

[41] Goto Y, Saito M, Iwasa T, et al. Japanese Cardiac Rehabilitation Survey Investigators. Poor implementation of cardiac rehabilitation despite broad dissemination of coronary interventions for acute myocardial infarction in Japan: a nationwide survey. Circ J 2007; 71: 173-9.

[42] Izawa KP, Oka K, Watanabe S, et al. Gender-related differences in clinical characteristics and physiological and psychosocial outcomes of Japanese patients at entry into phase II cardiac rehabilitation despite broad dissemination of coronary interventions for acute myocardial infarction in Japan: a nationwide survey. Circ J 2007; 71: 173-9.

[43] Otsu H, Moriyama M. Effectiveness of an educational self-management program for outpatients with chronic heart failure. Jpn J Nurs Sci 2011; 8(2): 140-52.

[44] Kato N, Kinugawa K, Ito N, et al. Gender-related differences in clinical characteristics and physiological and psychosocial outcomes of Japanese patients at entry into phase II cardiac rehabilitation despite broad dissemination of coronary interventions for acute myocardial infarction in Japan: a nationwide survey. Circ J 2007; 71: 173-9.

[45] Shen YQ, Jiang JF, Wang LM, et al. The effects of aerobic exercise on cardiac output during exercise in patients with chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2011; 39: 700-5.

[46] Wang W, Chair SY, Thompson DR, et al. Effects of home-based rehabilitation on health-related quality of life and psychological status in Chinese patients recovering from acute myocardial infarction. Heart Lung 2012; 41: 15-25.
[47] Chair SY, Chan SW, Thompson DR, et al. Short-term effect of motivational interviewing on clinical and psychological outcomes and health-related quality of life in cardiac rehabilitation patients with poor motivation in Hong Kong: a randomized controlled trial. Eur J Cardiovasc Prev Rehabil 2011.

[48] Chan CL, Wang CW, Ho RT, et al. A systematic review of the effectiveness of qigong exercise in cardiac rehabilitation. Am J Chin Med 2012; 40: 255-67.

[49] Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. J Am Coll Cardiol 2009; 53(15): e1-e90.

[50] Jenghua K, Jedsadayanmata A. Rate and predictors of early readmission among Thai patients with heart failure. J Med Assoc Thai 2011; 94: 782-8.

[51] Yu SB, Cui HY, Qin M, et al. The prognostic value of etiology in patients with chronic systolic heart failure. Zhonghua Liu Xing Bing Xue Za Zhi 2011; 32: 1148-52.

[52] Lee R, Chan SP, Chan YH, et al. Impact of race on morbidity and mortality in patients with congestive heart failure: a study of the multiracial population in Singapore. Int J Cardiol 2009; 134: 422-5.

[53] Kalogeropoulos A, Georgiopoulou V, Kritchevsky SB, et al. Epidemiology of incident heart failure in a contemporary elderly cohort: the health aging and body composition study. Arch Intern Med 2009; 169: 708-15.

[54] Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-26.

[55] Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008; 101: 1016-22.

[56] Butler J, Kalogeropoulos A. Worsening heart failure hospitalization epidemic we do not know how to prevent and we do not know how to treat! J Am Coll Cardiol 2008; 52: 435-7.

[57] Gheorghiade M, Zannad F, Sopko G, et al. International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 2005; 112: 3958-68.

[58] Shiba N, Nochioka K, Kohno H, et al. Emerging problems of heart failure practice in Japanese women: lessons from the CHART study. Circ J 2008; 72: 2009-14.

[59] Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S. Clinical characteristics and outcomes of heart failure with preserved ejection fraction: lessons from epidemiological studies. J Cardiol 2010; 55: 13-22.

[60] West R, Liang L, Fonarow GC, et al. Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. Eur J Heart Fail 2011; 13: 945-52.